4-YEAR SAFETY PROFILE CONSISTENT WITH THE GLP-1 RA CLASS 1, 5 ‡
NEW CV
INDICATION 1 †
Choose Wegovy ® to give your patients the weight loss they want and the heart protection they need 1 – 4 †
†
Wegovy ® is indicated for weight management in adults and adolescents, and for reduction in risk of CV events in adults with a BMI of ≥27 kg / m 2 and established CVD without diabetes. 1
WEIGHT LOSS
Achieved by ~ 1 in 3 patients treated over 68 weeks 1 – 3 #
REDUCTION IN MACE
vs placebo on top of CV SOC in adults with established CVD without diabetes 1, 4^
4-YEAR SAFETY PROFILE CONSISTENT WITH THE GLP-1 RA CLASS 1, 5 ‡
For more information about Wegovy ® 2.4 mg, including practical resources, upcoming educational events and the wegovycare ® patient support program, scan the QR code or visit wegovy. com. au
#
STEP 1 and 4: Mean weight loss of 15 – 17 %( p < 0.001 vs placebo) as an adjunct to a reduced-energy diet and increased physical activity in patients with a BMI of ≥27 kg / m 2 in the presence of at least one weight-related comorbidity or a BMI of ≥30 kg / m 2 regardless of a comorbidity; 30.2 % of patients in STEP 1 and 38.6 % of patients in STEP 4 achieved ≥20 % weight loss with Wegovy ®; supportive secondary endpoint, p-value not available, not to be used to infer definitive treatment effect. Mean baseline body weight and BMI of 105 – 107 kg and 37.9 – 38.4 kg / m 2, respectively. 1 – 3 ^SELECT: First occurrence of MACE( CV death, non-fatal myocardial infarction or non-fatal stroke) vs placebo to manage CV risk factors in adults with a BMI ≥27 kg / m 2 and established CVD without diabetes( HR 0.80, 95 % CI 0.72 – 0.90, p < 0.001). 1, 4 ‡ The overall safety profile in SELECT at 4 years did not reveal any new safety signals from prior STEP studies. 5 The most common side effects associated with Wegovy ® 2.4 mg in the STEP trials were gastrointestinal( nausea = 38 %, diarrhoea = 27 %, constipation = 22 %, vomiting = 22 %, abdominal pain = 18 %), headache( 13 %) and fatigue( 10 %). 1 Gastrointestinal adverse events were predominately of mild-to-moderate severity and subsided over time. 1 – 3 Across four 68-week phase III clinical trials of 2,650 adults who received Wegovy ® 2.4 mg, acute pancreatitis was reported in 0.2 % of patients. If suspected, Wegovy ® should be discontinued and only restarted once pancreatitis is ruled out. 1
This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www. tga. gov. au / reporting-problems.
PBS Information: This product is not listed on the PBS.
Please review full Product Information before prescribing, available at https:// rss. medsinfo. com. au / no / pi. cfm? product = nopwegov
Scan QR code to see full Wegovy ®( semaglutide 2.4 mg) Product Information
BMI: body mass index; CI: confidence interval; CV: cardiovascular; CVD: cardiovascular disease; GLP-1 RA: glucagon-like peptide-1 receptor agonist; HR: hazard ratio; MACE: major adverse cardiovascular event; SOC: standard of care.
References: 1. Wegovy ®( semaglutide 2.4 mg) Approved Product Information. Available at: https:// rss. medsinfo. com. au / no / pi. cfm? product = nopwegov. 2. Wilding JPH, et al. N Engl J Med. 2021; 384:989 – 1002( plus supplementary appendix). 3. Rubino D, et al. JAMA. 2021; 325:1414 – 25( plus supplementary appendix). 4. Lincoff AM, et al. N Engl J Med. 2023; 389:2221 – 32. 5. Ryan DH, et al. Nat Med. 2024; 30:2049 – 57.
Novo Nordisk Pharmaceuticals Pty Ltd. Level 10, 118 Mount Street, North Sydney NSW 2060. ABN 40 002 879 996. Novo Nordisk ® Medical Information( Australia) 1800 668 626. www. novonordisk. com. au. ® Registered trademark of Novo Nordisk A / S. NOOBOY0355d. AU25SEMO00211. August 2025.